COVID-19 antibodies persist, reduce reinfection risk for up to six months, study finds

The antibodies' ability to neutralize COVID-19 did not differ significantly over the six-month period.

5:00 AM

Author | Noah Fromson

Outline of a person with COVID Allergies
Graphic

A Michigan Medicine study found that most patients with mild COVID-19 infections produce antibodies that persist and protect them from reinfection for up to six months.

Researchers analyzed nearly 130 subjects with PCR-confirmed COVID-19 illness between three and six months after initial infection. Three patients were hospitalized while the rest were treated as outpatients and experienced mild infection, with symptoms including headaches, chills and loss of taste or smell.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

The results, published in Microbiology Spectrum, reveal approximately 90% of participants produced spike and nucleocapsid antibody responses, and all but one had persistent antibody levels at follow up.

"Previously, there was a lot of concern that only those with severe COVID-19 produced strong antibody responses to infection," said Charles Schuler, M.D., lead author of the paper and clinical assistant professor of allergy and immunology at Michigan Medicine. "We're showing that people with mild bouts of COVID-19 did really well after their infection, made antibodies, and kept them."

Achieving natural immunity by deferring vaccination in favor of infection is not worth going through the discomfort, risk to yourself and risk to others.
Charles Schuler, M.D.

The prospective study's participants were either Michigan Medicine health care workers or patients with a high risk of exposure to COVID-19. Most subjects took part in the same research team's previous study, which found that COVID antibody tests are effective at predicting prior infection.

SEE ALSO: COVID-19 Antibody Tests, Even Rapid Finger Pricks, are Effective, New Study Finds

During the observation period, none of the subjects who produced antibodies were re-infected, compared to 15 antibody-negative patients. Schuler's team also found that the antibodies' ability to neutralize COVID-19 did not differ significantly from the first visit, which occurred three months after infection, to the second visit at the six-month mark.

"While some studies have suggested antibodies against COVID-19 wane over time, these findings provide strong prospective evidence for longer-term immunity for those who produce an immune response to mild infection," said James Baker Jr., M.D., senior author of the paper and founding director of the Mary H. Weiser Food Allergy Center at Michigan Medicine. "To our knowledge, this is the first prospective study that demonstrates such a risk reduction for clinical reinfection in this specific type of population."

Impact on COVID vaccination

The team of researchers is now analyzing samples of this subject group taken up to a year after infection to further evaluate antibody responses. Meanwhile, they concluded that individuals with COVID-19 can delay vaccination for 90 days after infection ends. The Centers for Disease Control and Prevention recommends those treated with monoclonal antibodies or convalescent plasma wait 90 days after receiving treatment before getting vaccinated, and others should wait until they have recovered from COVID-19 and "have met the criteria to discontinue isolation."

SEE ALSO: Studying an extra COVID-19 vaccine dose in people with autoimmune diseases

A study conducted in Kentucky that found that unvaccinated people who already had COVID-19 were 2.34 times more likely than fully vaccinated people to be infected again, suggesting "vaccination provides additional protection against reinfection."

Additionally, the research was conducted between March 2020 and Feb. 2021, months before the highly transmissible Delta variant became the dominant strain of COVID in the United States.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Amid rising cases and hospitalizations, Schuler said, remaining unvaccinated comes with "a high price" for immunity.  

"These results are encouraging for those who have already run the gauntlet of COVID-19 infection," he said. "However, I do not recommend citing this study as a reason not to be vaccinated for those never previously infected. Vaccination decreases infectiousness, the risk of hospitalization and deaths from COVID-19, without having the actual infection. Achieving natural immunity by deferring vaccination in favor of infection is not worth going through the discomfort, risk to yourself and risk to others."

Paper cited: "Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies," Microbiology Spectrum. DOI: 10.1128/spectrum.00087-21


More Articles About: Lab Report Vaccines and Immunizations Immunizations Covid-19 Allergy and Immunology Occupational Health
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Health care provider loads syringe with measles vaccine
Health Lab
Measles: 10 things to know about immunization and prevention
Measles: 10 things to know about immunization and prevention
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
The Intersection of Artificial Intelligence & Alzheimer’s Disease and Related Dementias
In this episode, Matt and Donovan talk with Dr. Jason H. Moore, Director of the Center for Artificial Intelligence Research and Education (CAIRE) and Chair of the Department of Computational Biomedicine at Cedars-Sinai Medical Center. Jason discusses the coming impact of artificial intelligence on a spectrum of Alzheimer’s disease and related dementia (ADRD) issues. We discuss how tools such as AI-powered chatbots may improve quality of life for people living with dementia (and their caregivers) and how AI may contribute in the future to diagnosis and treatment.
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants
Woman sleeping on a couch holds her stomach, as if in pain
Health Lab
Long COVID-19 is linked to chronic pain conditions
Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID-19
Surgeon's tray with gloved hand reaching into wallet
Health Lab
Worries about costs, time off work and COVID-19 kept some older adults from having surgery
Elective surgery study shows older adults have concerns about what it will cost them, how much work they’ll miss and whether they’ll catch COVID-19.
Girl shielding eyes from virus illustration
Health Lab
Immunocompromised patients and COVID infections: Who’s at risk?
A prospective study published in the journal Lancet Microbe provides more clarity on which patient populations are at higher risk for prolonged infections — and hints that this fear is likely unwarranted.